Summary
This prediction ended on 17.11.21 with a price of €49.63. With a performance of 5.16%, the BUY prediction by Mori8 for Bayer AG closed with a slight gain. Mori8 has 50% into this predictionBayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Bayer AG | 2.085% | 2.085% | 94.963% | -33.660% |
| iShares Core DAX® | 4,24 % | 2,86 % | 14,03 % | 49,55 % |
| iShares Nasdaq 100 | 4,89 % | 2,81 % | 32,71 % | 85,97 % |
| iShares Nikkei 225® | 9,40 % | 7,83 % | 48,30 % | 63,32 % |
| iShares S&P 500 | 3,53 % | 1,95 % | 25,25 % | 62,38 % |
Comments by Mori8 for this prediction
In the thread Bayer AG diskutieren
Buy Bayer AG
https://www.deraktionaer.de/artikel/aktien/bayer-trotz-glyphosat-produktionsausfall-prognose-steht-20239303.html?feed=TRtvHrugxEKV2n-qR2P-ag
Die Aktien des Chemiegiganten Bayer können sich aktuell weiterhin über dem Widerstand bei 48,00 Euro halten. Die Long-Position ist weiterhin im Rennen, der Stopp wird nun auf Einstand nachgezogen.
Eine Long-Position wurde im Bereich von 48,00 Euro eröffnet. Der Stopp befindet sich bei 47,00 Euro und wird nun auf 48,00 Euro nachgezogen. Das Kursziel ist bei 49,50 Euro im oberen Trendkanalbereich zu sehen.
https://www.boerse-daily.de/boersen-nachrichten/insight-bayer-long-weiter-im-rennen
https://www.boerse-daily.de/boersen-nachrichten/insight-bayer-long-weiter-im-rennen
Bayer Lifts Core EPS Outlook; Q3 Adj. EBITDA Beats Consensus
- (PLX AI) - Bayer Q3 EBIT EUR 530 million vs. estimate EUR 1,200 million after net special charges of EUR 694 million.
- • Q3 revenue EUR 9,781 million vs. estimate EUR 9,120 million
- • Q3 net income EUR 85 million
- • Outlook FY adjusted EBITDA margin 26%
- • Outlook FY free cash flow EUR -1,500 to -500 million (previously: between approximately minus 2 billion euros and minus 3 billion euros) as a portion of the settlement payments for the glyphosate litigations are now expected to be made in 2022 instead of 2021
- • Outlook FY revenue currency-adjusted EUR 44,000 million (unchanged)
- • Bayer lifts core eps outlook
- • Bayer Core earnings per share are now expected to come in at approximately 6.50 euros to 6.70 euros, up from 6.40 euros to 6.60 euros
- • Q3 adjusted EBITDA EUR 2,089 million vs. estimate EUR 1,940 million
https://www.boersennews.de/nachrichten/artikel/bayer-treibt-nach-zahlen-kursrally-voran-basf-aktie-in-heikler-lage-/3310360/